LOGO roboto color with gray.png
Folia Health Technology Platform Used in First-of-its-Kind Real World Evidence Study for Sickle Cell Disease
September 15, 2022 15:23 ET | Folia Health
BOSTON, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Today, Folia Health announced the initiation of the ASCEND Study, a first-of-its-kind, at-home observational real-world evidence study in which people...
AMR Logo.png
Global Hemoglobinopathies Market is Expected to Reach $7.0 Billion by 2031: Says AMR
August 25, 2022 08:33 ET | Allied Market Research
Portland, OR, Aug. 25, 2022 (GLOBE NEWSWIRE) -- The Global Hemoglobinopathies Market size was estimated at $4.2 billion in 2021 and is expected to hit $7.0 billion by 2031, registering a CAGR of...
Straits Research Pvt Ltd
CRISPR Gene Editing Market Size is projected to reach USD 14.80 Billion by 2030, growing at a CAGR of 29.80%: Straits Research
August 01, 2022 12:40 ET | Straits Research
New York, United States, Aug. 01, 2022 (GLOBE NEWSWIRE) -- CRISPR Gene Editing, also called genome editing, modifies an organism's DNA. This method replaces, adds, or removes genetic material from...
Global Blood and Plasma Components Market Report 2022: A $66.47 Billion Market in 2031 - Increase in Adoption of Business Expansion Strategies in the Market
June 10, 2022 04:48 ET | Research and Markets
Dublin, June 10, 2022 (GLOBE NEWSWIRE) -- The "Blood and Plasma Components Market - A Global and Regional Analysis: Focus on Product, Application, End User and Region - Analysis and Forecast,...
Hemex Health announces breakthrough measurement capability for clinicians monitoring sickle cell disease therapy
May 08, 2022 06:00 ET | Hemex Health
PORTLAND, Ore. and MUMBAI, India, May 08, 2022 (GLOBE NEWSWIRE) -- Hemex Health, a Portland, Oregon-based health-tech startup, announced a significant enhancement to their Gazelle™ Hb Variant test,...
Imara-Logo-Color-RGB.jpg
Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)
January 25, 2022 07:00 ET | Imara, Inc.
Expanding patient base and potential of Imara’s small molecule oral inhibitor of phosphodiesterase-9 (PDE9) alongside hemoglobin disorders Phase 2 trial aims to select HFpEF patients with enriched...
22157.jpg
Worldwide Hematology Testing Industry to 2027 - by Product, Test Type, End-user and Geography
December 22, 2021 05:18 ET | Research and Markets
Dublin, Dec. 22, 2021 (GLOBE NEWSWIRE) -- The "Hematology Testing Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering. In-depth Analysis and...
Imara-Logo-Color-RGB.jpg
Imara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021
December 13, 2021 07:00 ET | Imara, Inc.
BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects...
Imara-Logo-Color-RGB.jpg
Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease
November 22, 2021 07:00 ET | Imara, Inc.
Primary endpoint to be changed to annualized rate of VOCs following written U.S. Food and Drug Administration recommendation No change to conduct or size of trial planned; Ardent trial remains on...
Imara-Logo-Color-RGB.jpg
Imara to Present Clinical and Preclinical Data at the American Society of Hematology (ASH) Annual Meeting 2021
November 04, 2021 09:17 ET | Imara, Inc.
Tovinontrine (IMR-687) VOC data in patients with sickle cell disease from ongoing Phase 2a open-label extension study and preclinical models of beta-thalassemia to be presented Oral presentation...